Screening Tests by Age: What Belongs on Your List in Each Decade

A woman of fifty-one arrives with a folder. Inside it is a complete executive checkup from last year: a stress test, an abdominal ultrasound, a full blood count, several pages of printed results. What it does not contain is a blood pressure reading taken more than once, an ApoB, or an answer to who in her family fell ill and at what age. She has had a great many tests. She has not had the screening tests by age that were relevant to her — and many of those were available to her through her health fund (kupat holim), in a scope that varies between funds and between supplementary insurance plans.

That is the gap worth closing. “The annual check-up” sounds like one thing you do once a year, but no such single test exists. What exists is a small collection of screening tests, each with its own starting age and interval, for which good evidence of improved outcomes has accumulated — and alongside them a far larger market of tests that are agreeable to undergo and almost never change a decision. This guide is organised by decade. It is a general guide rather than personal medical advice, and family history or existing disease shifts nearly every age in it.

What actually makes a screening test worth doing

A test earns its place when it satisfies three conditions at once: the disease is common enough to be worth looking for, there is an early and silent stage at which it can be caught, and an intervention exists that changes the course of events once it is. Plenty of impressive tests fail the third. They find something, but the knowledge leads to no action that improves your odds.

This is why the list is short and dull, and why much of it is already accessible through the health funds — within the national health basket or through supplementary insurance, in a scope and on terms that vary between funds and are updated from time to time. The value of this article is not in adding tests but in using what is already available to you, at the right age and the right frequency. We have written separately about the distinction between evidence-based screening and tests that mainly sell reassurance, in the article on early detection of cancer.

The twenties and thirties: build a baseline, do not hunt for disease

In these decades the prevalence of disease is low, so aggressive screening generates more noise than benefit. What is built here is a baseline — a series of measurements whose value emerges only a decade later, when there is something to compare them against.

• Blood pressure — among the best cost-to-benefit ratios in medicine. Hypertension in the thirties is not rare, and it is entirely without symptoms. A single clinic reading is not a diagnosis; a high value calls for repeat measurements at home.
• Lipid profile — at least once in the twenties, and every few years thereafter.
• Lp(a) — largely determined genetically, so a single measurement once in a lifetime is usually enough. A high value tightens the treatment targets for the other risk factors, and points to a family risk nobody knew was there.
• Fasting glucose and HbA1c — a baseline for long-term tracking of the metabolic trajectory.
• Cervical screening for women — the starting age depends on which guideline applies, and ranges from the early twenties to the mid-thirties. The international shift from cytology to HPV testing as the primary test allows longer intervals; in Israel the entitlement within the national health basket, the ages and the frequency are not identical to every international guideline and vary between supplementary insurance plans as well. Worth asking about explicitly.
• Documenting your family history — not a test, and yet the thing that will matter more here than any test you undergo this decade. Who fell ill, with what, and at what age.

The forties: the decade the numbers begin to move

The question “which tests are recommended at forty” usually comes up right on time. This is the decade in which atherosclerosis accumulates quietly, insulin resistance begins to declare itself, and breast cancer screening comes up for discussion. It is also the decade in which it is easy to settle for “everything is normal” and postpone the question for another year.

On the cardiometabolic side, two things change. The first is a move from “are the values within range” to genuine risk estimation — blood pressure, lipids, glucose, smoking and family history combined into a quantitative estimate. The second is ApoB, which counts the atherogenic particles rather than only the cholesterol they carry. ApoB is not part of the routine check-up in most places, but it is measured on a simple blood test; you can ask for it, and coverage varies. In a person with a “normal” LDL-C and a raised ApoB, the treatment decision may change.

Mammography enters the discussion here. Most guideline bodies accept that mammographic screening reduces breast cancer mortality; what is contested is the size of the benefit, the starting age, the interval, and the weight given to overdiagnosis. In Israel the national programme invites women at average risk from roughly age fifty, and brings the start forward for women with an affected first-degree relative; the details of entitlement and frequency are updated from time to time and are worth verifying with your health fund. A woman of forty-two with no family background is not in a position of unambiguous guidance but of shared decision-making — and she deserves a conversation rather than being automatically put off for a decade.

Colorectal screening may also begin here. With a first-degree relative affected by colorectal cancer, the accepted rule is colonoscopy from age forty, or ten years before the age at which that relative was diagnosed — whichever comes first.

Much of the gap between what is recommended and what is done is not a gap of knowledge or of money. It is a gap of booking an appointment. The highest-value test for many readers here is the one already open in their name, already overdue, and simply never scheduled.

The fifties: the busiest decade

If there is one decade in which it pays to be organised, this is it. Almost all of the established screening programmes run in parallel.

Colorectal cancer. In Israel the national programme is built on an annual faecal immunochemical test (FIT), generally from age fifty to the mid-seventies, with colonoscopy following a positive result. That is a legitimate and effective programme at population level — on one critical condition: that a positive result is followed by colonoscopy without delay. Colonoscopy as the first-line test is an alternative, and it is unusual in being not merely diagnostic but preventive, because removing adenomatous polyps takes away the lesions from which most tumours develop. Several international guidelines have in recent years brought the starting age forward to forty-five, following a rise in incidence at younger ages; the starting age in the Israeli programme is not necessarily the same, and it is worth checking with your fund what applies to you.

Mammography becomes an active invitation here — in Israel generally once every two years, while some international guidelines recommend an annual interval. Lung cancer screening with low-dose chest CT has been shown to reduce mortality in people with a substantial smoking history, and uptake is lowest precisely in the group with the most to gain. In Israel it is not organised as a national screening programme in the same way, and availability and coverage vary — anyone who smoked for many years would do well to raise it with their physician on their own initiative. Skin examination by a dermatologist is relevant in the Israeli population, with its high cumulative sun exposure; to be precise, routine skin screening of the whole population is not supported by evidence of the same strength as the other programmes here, and the benefit is clearer in people with many moles, fair skin, childhood sunburn or a family history.

In women, menopause changes several things at once: the rate of bone loss rises, the lipid profile usually worsens, and body composition shifts. It is a natural point for reassessment rather than for continued inertia.

Sixty and beyond: what is added, and what can stop

This decade brings in tests whose value is functional at least as much as diagnostic. Bone density (DXA) enters for postmenopausal women — usually around age sixty-five at average risk, and earlier with a previous fracture, prolonged steroid treatment, low body weight or a family history of hip fracture. A first osteoporotic fracture is an event that changes the course of a life, and its risk can be reduced substantially. Periodic eye examination detects glaucoma — symptomless through most of its course and a cause of irreversible vision loss — as well as cataract and macular degeneration. Hearing testing is often neglected, and unjustly so: hearing loss is associated with social isolation and cognitive decline, and treatment is available and relatively simple. How far correcting hearing itself slows cognitive decline is still under study, but the functional and social benefit is clear.

It matters just as much to say when screening stops. Cancer screening is intended for someone who will live long enough to benefit from it, and in older age or in the presence of another serious illness the balance between benefit and harm reverses. Stopping at the appropriate age is not a concession. It is a legitimate clinical decision, better made in a conversation than through a quiet disappearance from the invitation list.

Screening tests by age — the consolidated picture

What the table does not show is the difference between a recommended frequency and a frequency somebody actually keeps to. A screening programme exists only to the extent that it is carried out.

Family history and personal risk move the ages

Every number in the table was written for a person at average risk. Many readers are not that person. The following patterns justify a formal risk assessment, and sometimes genetic counselling, rather than reassurance:

• Cancer diagnosed at an unusually young age in the family — breast or colorectal disease before fifty, for instance
• Several relatives on the same side of the family with related tumours
• Ashkenazi Jewish ancestry, in which founder BRCA variants are markedly more common
• An early cardiac event in a first-degree relative — before fifty-five in a man, sixty-five in a woman
• Type 2 diabetes in both parents, or a history of gestational diabetes
• Osteoporosis or hip fracture in a parent

In these cases the age at which screening starts is earlier, the interval between tests is shorter, and sometimes the test itself is different — breast MRI rather than mammography alone, colonoscopy rather than FIT, early assessment of subclinical atherosclerosis rather than waiting for an event.

Turning this into a schedule that actually happens

Much of what is written here is accessible through your family physician in the health fund, and sometimes through supplementary insurance or directly in the fund’s app. The following actions are worth more than any additional test you might add:

• Find out what you are currently being invited for. The health funds maintain screening registers and invitation lists; whatever is open there in your name is the starting point, before any private test.
• Book the overdue items first. A colonoscopy, mammogram or cervical screen deferred by two years is usually the most significant gap in your medical record.
• Bring your family history in writing to the appointment. Five accurate lines change more than ten additional tests.
• Do not let an executive checkup replace the list. It is usually thorough on blood work and general imaging, but does not necessarily include the screening tests shown to reduce mortality — those remain your responsibility and your family physician’s.
• Add deliberately, not reflexively. ApoB, Lp(a) and fasting insulin are reasonable additions at most ages. Whole-body scans and broad panels are a separate decision, with a real cost in incidental findings.

This is also why we begin every assessment by mapping what has already been done and what is missing, before adding any layer of comprehensive testing. A guide by age is a good starting point for a conversation with your physician, not a substitute for one. The questions worth asking are plain: which screening tests should I be having now, given my age; when did I last have each of them; and is there anything in my background that takes me off the average-risk pathway.